Surmodics Inc: (NASD: SRDX)

$26.12

-0.01 (-0.04%)

Volume 1,000

May 23 09:57 AM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		25.88 - 26.12
	
		52wk Low - High
		13.53 - 27.98
	
		Previous Close
		26.13
	
		Avg. Volume
		108,428
	
		Industry
		MED PRODUCTS
	
		Market Cap
		383.17 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.13
	
		PE (Forward)
		28.71
	
		Current Year Est.
		0.91
	
		Quarterly Earnings ESP 
		-9.09%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
NA

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		177 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/9/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            28.71
                        
                            PEG Ratio
                            1.91
                        
                            Current Year Est.
                            0.91
                        
                            Current Quarter Estimate
                            0.22
                        
                            Most Accurate Estimate
                            0.20
                        
                            Earnings ESP 
                            -9.09%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            0.78
                        
                            Expected Earnings Growth
                            15.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.   
Full SRDX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
SRDX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (09/2013)	Next Year (09/2014)
Average Estimate	0.22	0.22	0.91	0.95
Number of Estimates	3	3	2	3
Low Estimate	0.20	0.21	0.85	0.90
High Estimate	0.24	0.25	0.97	NA
Year Ago EPS	0.17	0.19	0.61	0.91
EPS Growth	27.45%	17.54%	49.18%	4.03%

More SRDX Estimates

Average Earnings Estimates for SRDX

EPS Growth for SRDX

Industry Analysis

Name	Symbol	Previous Close
SURMODICS	SRDX	26.13
ATRICURE INC	ATRC	9.14
CONCEPTUS INC	CPTS	30.94
INVIVO THERAPT	NVIV	2.90
TRANS1 INC	TSON	1.80
ABAXIS INC	ABAX	43.51
ADVAXIS INC	ADXS	0.04
BAXTER INTL	BAX	72.30
BIO-RAD LABS -A	BIO	115.39
BIOLIFE SOL INC	BLFS	0.37

Sector:Medical>> Industry:MED PRODUCTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Earnings Miss at SurModics

May 08, 2013

Back to Neutral on SurModics

Feb 25, 2013

Earnings Beat at SurModics

Jan 31, 2013

Haemonetics Upgraded to Outperform

Jan 11, 2013

SurModics Upgraded to Strong Buy

Jan 11, 2013

SurModics Recruits New Finance Head

Dec 28, 2012

Zacks Bull and Bear of the Day Highlights: PerkinElmer, Advance Auto Parts, SurModics, 3M Company and Johnson & Johnson

Nov 23, 2012

SurModics Reverts to Neutral

Nov 21, 2012

More SRDX Zacks Commentary

Financials

EPS TTM	0.78
Sales	52
Net Income	14
Price/Earnings	33.50
Price/Book	3.76
Price/Cash Flow	28.06
Price/Sales	6.92

More SRDX Financials

News

SurModics to Present at Jefferies Global Healthcare Conference - Close-Up Media

May 23, 2013

SurModics to Present at the Jefferies Global Healthcare Conference - Businesswire

May 21, 2013

SurModics Makes a Move: Down 1.5% - Financial News Network Online - Market Movers

May 20, 2013

SurModics reports higher Q2 net income, provides outlook for fiscal 2013 - Datamonitor

May 20, 2013

1 Reason SurModics May Be Headed for a Slowdown - TheMotleyFool

May 16, 2013

SurModics Releases 2Q Fiscal 2013 Results - Close-Up Media

May 12, 2013

SurModics Reports Second Quarter Fiscal 2013 Results - Close-Up Media

May 10, 2013

Earnings Miss at SurModics - Zacks.Com

May 9, 2013

See All News Stories on SRDX

Broker Recommendations

Current ABR	2.50
ABR (Last Week)	2.50
# of recs in ABR	2
Average Target Price	28.08
Industry Rank by ABR	184 out of 265
Rank in Industry	5 out of 73

More SRDX Broker Recommendations

Day Low - High	25.88 - 26.12
52wk Low - High	13.53 - 27.98
Previous Close	26.13
Avg. Volume	108,428
Industry	MED PRODUCTS
Market Cap	383.17 M
Div - Yield	0.00 - 0.00
Beta	1.13
PE (Forward)	28.71
Current Year Est.	0.91
Quarterly Earnings ESP	-9.09%

PE (Forward)	28.71
PEG Ratio	1.91
Current Year Est.	0.91
Current Quarter Estimate	0.22
Most Accurate Estimate	0.20
Earnings ESP	-9.09%
Next Earnings Report Date	08-07-2013
EPS Last Year	0.78
Expected Earnings Growth	15.00%

Username: Password:

Remember me [?]

Surmodics Inc: (NASD: SRDX)

$26.12

-0.01 (-0.04%)

Volume 1,000

May 23 09:57 AM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description